Evidence map›Paper›PMID 33946220›Full record

ArticleCancers2021

Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34

Pavla Koralkova, Monika Belickova, David Kundrat, Michaela Dostalova Merkerova, Zdenek Krejcik, Katarina Szikszai, Monika Kaisrlikova, Jitka Vesela, Pavla Vyhlidalova, Jan Stetka and 7 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Pavla KoralkovaDepartment of Biology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 775 15 Olomouc, Czech Republic.ORCID 0000-0001-7970-1501
Monika BelickovaInstitute of Hematology and Blood Transfusion, 128 20 Prague, Czech Republic.ORCID 0000-0002-9158-881X
David KundratInstitute of Hematology and Blood Transfusion, 128 20 Prague, Czech Republic.
Michaela Dostalova MerkerovaInstitute of Hematology and Blood Transfusion, 128 20 Prague, Czech Republic.ORCID 0000-0002-6345-9180
Zdenek KrejcikInstitute of Hematology and Blood Transfusion, 128 20 Prague, Czech Republic.
Katarina SzikszaiInstitute of Hematology and Blood Transfusion, 128 20 Prague, Czech Republic.
Monika KaisrlikovaInstitute of Hematology and Blood Transfusion, 128 20 Prague, Czech Republic.
Jitka VeselaInstitute of Hematology and Blood Transfusion, 128 20 Prague, Czech Republic.
Pavla VyhlidalovaDepartment of Biology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 775 15 Olomouc, Czech Republic.ORCID 0000-0002-2522-6749
Jan StetkaDepartment of Biology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 775 15 Olomouc, Czech Republic.ORCID 0000-0003-4301-2856
Alzbeta HlavackovaInstitute of Hematology and Blood Transfusion, 128 20 Prague, Czech Republic.
Jiri SuttnarInstitute of Hematology and Blood Transfusion, 128 20 Prague, Czech Republic.ORCID 0000-0003-4305-9718
Patrik FlodrDepartment of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, 775 15 Olomouc, Czech Republic.
Jan StriteskyInstitute of Pathology, First Faculty of Medicine Charles University and General University Hospital, 128 08 Prague, Czech Republic.
Anna JonasovaFirst Department of Medicine, First Faculty of Medicine Charles University and General University Hospital, 128 08 Prague, Czech Republic.
Jaroslav CermakInstitute of Hematology and Blood Transfusion, 128 20 Prague, Czech Republic.
Vladimir DivokyDepartment of Biology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 775 15 Olomouc, Czech Republic.ORCID 0000-0003-0202-245X
Institute of Haematology and Blood Transfusion · CZPalacký University Olomouc · CZCharles University · CZUniversity Hospital Olomouc · CZ

Funding

Czech Health Research Council NV16-33485AInternal Grant Agency of Palacky University IGA_LF_2020_005Ministry of Health of the Czech Republic 00023736
6 · The paper itself

Abstract

To better understand the molecular basis of resistance to azacitidine (AZA) therapy in myelodysplastic syndromes (MDS) and acute myeloid leukemia with myelodysplasia-related changes (AML-MRC), we performed RNA sequencing on pre-treatment CD34

Indexed as

azacitidine therapyhistone acetylationIDH2metabolic signaturemyelodysplastic syndromes

Identifiers

PMID33946220
PMCPMC8125503
OpenAlexW3159701899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.